What is it about?
I shortly review the current knowhow on diagnosis and immunoglobulin treatment of secondary (i.e. caused By an external factor like treatment) immunodeficiencies and also pinpoint the patient groups which clearly would need to be studied or re-studied.
Featured Image
Why is it important?
Immunoglobulin replacement therapy is expensive and, based onvolunteer donations, its availability is limited. Thus it should be used prudently. However, in certain situations it is clearly life saving. Yet, even in some very severe immunoglobulin deficiencies we lack studies.
Perspectives
This publication was born out of the frustration that we have no available treatment data or even clinical descriptive studies on severe and permanent lack of immunoglobulins in patients with previously treated lymphoma in remission. And this despite the fact that these patients are clinically exact phenocopies of common variable immunodeficiency patients, and may even represent the same patient cohort, only the onset of their disease begins not with infections but lymphoma. In common variable immunodeficiency, if you treat patients with adequate doses of IgG, they live up to more than 30 years longer.
Mikko Seppänen
Helsinki University Central Hospital
Read the Original
This page is a summary of: Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies, Clinical & Experimental Immunology, December 2014, Wiley,
DOI: 10.1111/cei.12493.
You can read the full text:
Contributors
The following have contributed to this page
